單克隆抗狂犬病

德國(guó)進(jìn)口狂犬病單克隆抗體（FITC）

Monoclonal Anti-Rabies, FITC

用直接免疫熒光技術(shù)檢測(cè)狂犬病毒。單克隆抗狂犬病，F(xiàn)ITC用于印象涂片檢測(cè)（準(zhǔn)備，例如，從可疑的動(dòng)物腦組織）或用直接免疫熒光技術(shù)在細(xì)胞培養(yǎng)分離病毒。傳統(tǒng)的狂犬病病毒敏感的檢測(cè)以及蝙蝠相關(guān)的狂犬病病毒屬，尤其是和EBLV-2 EBLV-1

Monoclonal Anti-Rabies, FITC

Detection of rabies virus using the direct immunfluores-cence technique. Monoclonal Anti-Rabies, FITC is used for detection in impression smears (prepared, for example, from brain tissues of suspicious animals) or by virus isolation in cell cultures using the direct immunofluores- cence technique. Sensitive detection of the traditional rabies virus as well as bat-associated Lyssaviruses, especially EBLV-1 and EBLV-2

德國(guó)進(jìn)口狂犬病單克隆抗體（FITC）

單克隆抗體(MAb)與抗血清(又稱多克隆抗體，PAb)zui主要的區(qū)別是MAb為單一種B細(xì)胞克隆所產(chǎn)生的一種均一的免疫球蛋白分子。所以MAb是B細(xì)胞克隆的標(biāo)志，是一種*型的抗體，它的特異性是針對(duì)一個(gè)抗原決定簇的。制備單克隆抗體不能用化學(xué)分離的方法從多克隆抗體中去分離純化得到它，而是用分離產(chǎn)生抗體的B細(xì)胞克隆的方法得到它。為了使B細(xì)胞克隆能在體外人工培養(yǎng)下長(zhǎng)期存活并產(chǎn)生*均一的MAb，G．KÖhler合Milstein于1975年創(chuàng)立了雜交瘤方法。所以制備單克隆抗體的技術(shù)又稱雜交瘤技術(shù)(hybredoma technique)。

雜交瘤技術(shù)的基本原理是用分泌抗體但不能長(zhǎng)期培養(yǎng)的B細(xì)胞與能在體外長(zhǎng)期培養(yǎng)并可低溫保存的腫瘤細(xì)胞進(jìn)行雜交。篩選得到的雜交瘤細(xì)胞應(yīng)該是既能分泌抗體又有瘤細(xì)胞的特性，可長(zhǎng)期傳代培養(yǎng)，又可在液氮中保存的細(xì)胞。把這些細(xì)胞單克隆化，用單克隆化的雜交瘤細(xì)胞進(jìn)行單克隆抗體的生產(chǎn)。

The most important difference between the monoclonal antibody (MAb) and the antiserum (also called the polyclonal antibody, PAb) is that MAb is a homogeneous immunoglobulin produced by a single B cell clone. Therefore, MAb is a marker of B cell clone, and is a unique type of antibody. Its specificity is directed against an antigenic determinant. The preparation of monoclonal antibodies can not be separated and purified from polyclonal antibody by chemical separation, but it is obtained by the method of cloning the B cell that separates the antibody. In order to make B cell clones capable of long-term survival in vitro and produce a fully homogeneous MAb, G.KÖ hler and Milstein established a hybridoma method in 1975. Therefore, the preparation of monoclonal antibodies is also known as hybridoma technology (hybredoma technique).

The basic principle of hybridoma technique is to hybridize B cells that secrete antibodies but can not be cultured for a long time with cancer cells that can be cultured in vitro and can be preserved at low temperature in vitro. The screened hybridoma cells should be capable of secreting antibodies and tumor cells, which can be cultured for a long time and can be stored in liquid nitrogen. These cells were mcabled and monoclonal antibodies were produced with monoclonal hybridoma cells.

更多產(chǎn)品及服務(wù)請(qǐng)通過以下

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢

【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

單抗制品即為單克隆抗體（Monoclonal antibody，簡(jiǎn)稱McAb）制品，其由雜交瘤細(xì)胞生產(chǎn)，單克隆抗體其制品純度高、專一性強(qiáng)、效價(jià)高，使用時(shí)可免除不同細(xì)胞及微生物種或株間血清學(xué)上的交叉反應(yīng)，大大提高了診斷的特異性及敏感性。

制備過程

3.選擇性培養(yǎng)

選擇性培養(yǎng)的目的是篩選融合的雜交瘤細(xì)胞，一般采用HAT選擇性培養(yǎng)基。在HAT培養(yǎng)基中，未融合的骨髓瘤細(xì)胞因缺乏次黃嘌呤-鳥嘌呤-磷酸核糖轉(zhuǎn)移酶，不能利用補(bǔ)救途徑合成DNA而死亡。 未融合的淋巴細(xì)胞雖具有次黃嘌呤-鳥嘌呤-磷酸核糖轉(zhuǎn)移酶，但其本身不能在體外長(zhǎng)期存活也逐漸死亡。 只有融合的雜交瘤細(xì)胞由于從脾細(xì)胞獲得了次黃嘌呤-鳥嘌呤-磷酸核糖轉(zhuǎn)移酶，并具有骨髓瘤細(xì)胞能無限增殖的特性，因此能在HAT培養(yǎng)基中存活和增殖。

4.雜交瘤陽性克隆的篩選與克隆化

在HAT培養(yǎng)基中生長(zhǎng)的雜交瘤細(xì)胞，只有少數(shù)是分泌預(yù)定特異性單克隆抗體的細(xì)胞，因此，必須進(jìn)行篩選和克隆化。通常采用有限稀釋法進(jìn)行雜交瘤細(xì)胞的克隆化培養(yǎng)。采用靈敏、快速、特異的免疫學(xué)方法，篩選出能產(chǎn)生所需單克隆抗體的陽性雜交瘤細(xì)胞，并進(jìn)行克隆擴(kuò)增。經(jīng)過全面鑒定其所分泌單克隆抗體的免疫球蛋白類型、亞類、特異性、親和力、識(shí)別抗原的表位及其分子量后，及時(shí)進(jìn)行凍存。